NASDAQ:ORPN Bioblast Pharma (ORPN) Stock Price, News & Analysis → (Free Workshop) Advanced “bug-out bag” hacks! (From Warrior Life) (Ad) Free ORPN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.41▼$1.5250-Day Range$11.50▼$28.4952-Week Range$6.16▼$30.00Volume47,502 shsAverage VolumeN/AMarket Capitalization$613,200.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesTrendsStock AnalysisCompetitorsHeadlinesTrends Get Bioblast Pharma alerts: Email Address Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Bioblast Pharma Stock (NASDAQ:ORPN)Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.Read More Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution ORPN Stock News HeadlinesMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma on Strong Program Prospects and Competitive EdgeMay 16, 2024 | msn.comResearchers discover new family of bacteria with high pharmaceutical potentialMay 13, 2024 | markets.businessinsider.comPromising Sales Growth and Strong Clinical Prospects Underpin Buy Rating for Urogen PharmaApril 23, 2024 | msn.comUmbrella Labs Elevates Biotechnological Frontiers with Launch of ALPHA MSH PEPTIDE 10MG VIALApril 10, 2024 | markets.businessinsider.comEssential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastomaMarch 14, 2024 | barrons.comAnaptysBio Inc.February 23, 2024 | msn.comWhat's Going On With Rare/Orphan Disease Focused-Biodexa Pharmaceuticals Stock Friday?February 23, 2024 | morningstar.comLantern Pharma Inc Ordinary Shares LTRNFebruary 18, 2024 | msn.comQBiotics wins FDA orphan status for rainforest-derived cancer drugFebruary 18, 2024 | seekingalpha.comPBSV Pharma-Bio Serv, Inc.February 5, 2024 | markets.businessinsider.comAnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic SclerosisJanuary 4, 2024 | markets.businessinsider.comLumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical OfficerNovember 3, 2023 | marketwatch.comPlus Therapeutics Shares Jump Premarket on FDA Orphan DesignationMarch 31, 2023 | wsj.comChangzhou Qianhong Bio-Pharma Co. Ltd. AMarch 1, 2023 | marketwatch.com2023 Spinal Muscular Atrophy Medicine Market Report has the Potential to Deliver Genuine Review for DevelopmentFebruary 18, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market Size Global Research Report, 2023 - 2028February 15, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market 2023 | Size, Growth Rate, Key Players Share, And Industry Trends Analysis with Global Forecast 2023-2028February 13, 2023 | thestreet.comBioBlast Scant Data Links Drug to Improved Swallowing in PatientsJanuary 30, 2023 | seekingalpha.comBioMarin: Opportunity To Score Home Run With Latest Regulatory AdvancementsJanuary 18, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028October 16, 2022 | finance.yahoo.comOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027September 21, 2022 | seekingalpha.comENLV Enlivex Therapeutics Ltd.August 31, 2022 | marketwatch.comBioCryst Gets FDA Orphan Status for BCX9250 in Fibrodysplasia Ossificans ProgressivaAugust 31, 2022 | msn.comBioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease CandidateAugust 12, 2022 | finance.yahoo.comAro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe DiseaseSee More Headlines Receive ORPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioblast Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ORPN CUSIPN/A CIK1596812 Webbioblastpharma.com Phone(722) 670-8072FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.56 per share Price / Book0.19Miscellaneous Outstanding Shares420,000Free FloatN/AMarket Cap$613,200.00 OptionableNot Optionable Beta1.41 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesOren HershkovitzChief Executive OfficerShachar ShlosbergerChief Financial OfficerDror MevorachChief Scientific & Medical OfficerOdelia Ben-ShitritHead-Clinical OperationsKey CompetitorsPaxMedicaNASDAQ:PXMDCohBarNASDAQ:CWBRSeelos TherapeuticsNASDAQ:SEELAltamira TherapeuticsNASDAQ:CYTOInMed PharmaceuticalsNASDAQ:INMView All Competitors ORPN Stock Analysis - Frequently Asked Questions When did Bioblast Pharma's stock split? Bioblast Pharma shares reverse split on Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Bioblast Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Verastem (VSTM), Voyager Therapeutics (VYGR), Athersys (ATHX), ContraFect (CFRX), CTI BioPharma (CTIC) and Eleven Biotherapeutics (EBIO). This page (NASDAQ:ORPN) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.